61 /100
HIGH RISK
Score updated Jul 14, 2026

BCDA — BioCardia, Inc. Dilution Risk Tracker

Track BCDA dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track BCDA — Get alerts when the score changes →

As of July 14, 2026, BioCardia, Inc. (BCDA) has a DilutionWatch DilutionScore of 61/100, rated HIGH dilution risk. BioCardia, Inc. has a market capitalization of $10.58M, 11.37M shares outstanding, 18 institutional holders tracked. Key dilution vectors include 296.3K outstanding warrants, approximately 4 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
85
📊 Float Risk
30
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
35%
🔄 Reverse Split 45%
• 50-day avg $1.12 approaching $1 threshold
• Only 4 months cash — financial pressure
💰 Capital Raise 35%
• Low cash runway: 4 months remaining
📉 Score Deterioration 10%
• Score in HIGH risk zone (61/100)
🔔 Track BCDA — Get forecast alerts →

💹 Market Data

Market Cap$10.58M
Shares Outstanding11.37M
Float8.76M
Cash$2.75M
Debt$412.0K
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 25.7% shares (2026Q1 vs prior)
18 institutional holders · 817.4K shares
#1 VANGUARD CAPITAL MANAGEMENT LLC 249.2K shares
#2 CM Management, LLC 130.0K shares
#3 GEODE CAPITAL MANAGEMENT, LLC 94.3K shares
+ 15 more holders Sign up free to view →

📉 Short Interest

Short Interest371.8K
Days to Cover1.0
% of Float4.2%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Mar 31, 2026
xbrl XBRL CONVERTIBLE Dec 31, 2019
4 INSIDER TRANSACTION Apr 22, 2026
4 INSIDER TRANSACTION Mar 26, 2026
4 INSIDER TRANSACTION Feb 04, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for BCDA Shareholders

BioCardia, Inc. (BCDA) has a DilutionScore of 61/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

DilutionWatch tracks 296,296 outstanding warrants for BCDA. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window. Cash runway is a key watch item: BCDA has approximately 4 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for BCDA in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for BCDA alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.

Warrants Explained →
Track BCDA Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking BCDA — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for BCDA
📊 BCDA FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 BCDA Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.